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Background: There is excess cardiovascular mortality in patients with chronic obstructive 
pulmonary disease. Aortic stiffness, an independent predictor of cardiovascular risk, and systemic 
and airway inflammation are increased in patients with the disease. Statins modulate aortic 
stiffness and have anti-inflammatory properties. A proof-of-principle, double-blind, randomized 
trial determined if 6 weeks of simvastatin 20 mg once daily reduced aortic stiffness and systemic 
and airway inflammation in patients with chronic obstructive pulmonary disease.
Methods: Stable patients (n=70) were randomized to simvastatin (active) or placebo. Pre-
treatment and post-treatment aortic stiffness, blood pressure, spirometry, and circulating and 
airway inflammatory mediators and lipids were measured. A predefined subgroup analysis was 
performed where baseline aortic pulse wave velocity (PWV) was 10 m/sec.
Results: Total cholesterol dropped in the active group. There was no significant change in aortic 
PWV between the active group and the placebo group (-0.7 m/sec, P=0.24). In those with aortic 
stiffness 10 m/sec (n=22), aortic PWV improved in the active group compared with the placebo 
group (-2.8 m/sec, P=0.03). Neither systemic nor airway inflammatory markers changed. 
Conclusion: There was a nonsignificant improvement in aortic PWV in those taking simvastatin 
20 mg compared with placebo, but in those with higher baseline aortic stiffness (a higher risk 
group) a significant and clinically relevant reduction in PWV was shown. 
Keywords: chronic obstructive pulmonary disease, arterial stiffness, statins
Introduction 
Cardiovascular (CV) disease is a common comorbidity in COPD.1 Yet other than 
smoking cessation, routine COPD management is not currently focused on preventing 
CV disease. The risk of CV disease in COPD is two to three-fold greater than the risk 
generated by smoking,2 and CV disease accounts for more than a quarter of deaths in 
COPD patients.3 In other chronic diseases with an increased CV risk, statins have a 
role in CV prevention.4 There is limited but supportive retrospective and observational 
evidence for a cardioprotective role of statins in COPD.5,6 In healthy people with 
normal lipid levels but increased C-reactive protein (CRP) levels, atorvastatin in a 
large, randomized controlled trial (RCT) significantly reduced CRP and importantly 
the incidence of CV events.7
Aortic stiffness is an independent predictor of CV risk,8,9 and is increased in sub-
jects with COPD compared with smokers without COPD.10,11 The ability of statins 
to modulate aortic stiffness has been demonstrated in people with coronary artery 
disease independent of their lipid-lowering effects and in those with isolated systolic 
hypertension and normal cholesterol levels.12,13 Further, statins improve aortic stiffness 
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and systemic inflammation in other chronic inflammatory 
conditions, such as rheumatoid arthritis.14 
COPD is an inflammatory disease reflected in increased 
airway and circulating inflammatory markers. The persist-
ing systemic inflammatory state may well be central to 
many of the comorbidities of COPD, including CV disease, 
and decreasing inflammation may alter disease course.15,16 
Statins confer pleiotropic benefits in reducing inflammatory 
mediators, including the COPD-relevant markers of CRP 
and matrix metalloproteinase (MMP)-9.14,17 Whilst a recent 
large RCT of simvastatin in COPD reported no change in 
the primary outcome of exacerbation rate or time to first 
exacerbation,18 no RCT has examined CV disease as a pri-
mary outcome measure in COPD.
Statins are currently prescribed to patients with COPD 
needing secondary CV prevention. The role in primary pre-
vention is not known. We hypothesized that treatment with 
simvastatin 20 mg once daily would reduce aortic stiffness 
compared with placebo in a group of well characterized 
patients with COPD without coexistent ischemic heart dis-
ease, diabetes, or hypercholesterolemia. A 20 mg dose was 
selected as previous work indicates benefit at lower doses 
without the incremental musculoskeletal side effects.19 Our 
secondary hypothesis was that the heightened systemic and 
airway inflammation would be lowered in the active treatment 
group compared with the placebo group. 
Materials and methods
subjects
Clinically stable patients (n=70) with confirmed COPD, ie, 
forced expiratory volume in one second (FEV
1
) 30%–80% 
predicted, FEV
1 
to forced vital capacity (FVC) ratio (FEV
1
/
FVC) 0.7, salbutamol reversibility 12% and 200 mL, 
and a supportive smoking history were recruited into this 
double-blind, randomized, parallel-group, placebo-controlled 
study. Clinical stability was defined as no change in regular 
therapy in the preceding 4 weeks or change in symptoms 
beyond day-to-day variation. Exclusion criteria included 
prescribed statin or fibrate, hypercholesterolemia (total 
cholesterol 6.5 mmol/L), documented ischemic heart 
disease, and diabetes mellitus. The full inclusion/exclusion 
criteria are provided in the Supplementary materials. 
Subjects were recruited from departmental databases of 
volunteers, advertisements, and outpatient clinics, and with 
assistance from the Primary Care Research Network. Ethical 
(REC 10/H0408/10) and governance (including Medicines 
and Healthcare Products Regulatory Agency) approvals 
were granted (clinical trials identifier NCT01151306). The 
study was performed at a single center, ie, Nottingham 
Respiratory Research Unit, University of Nottingham, 
City Hospital Campus, Nottingham, from July 2010 to 
March 2013. Subjects gave written informed consent and 
the study was performed according to the Declaration of 
Helsinki. Measurements were performed pre-treatment and 
after 6 weeks (±3 days). Subjects were randomized 1:1 in 
a double-blind fashion, stratified by age (45–62 years and 
63–80 years), to either simvastatin (active) or placebo using 
a computer-generated code of random permuted blocks of 
randomly varying size by the clinical trials unit. The sequence 
was stored in the pharmacy and concealed from investigators 
and participants. Treatment allocation was performed by an 
independent pharmacist. The active treatment and placebo 
had an identical capsule appearance, the simvastatin being 
overencapsulated. 
Cardiovascular measurements
Having refrained from short-acting and long-acting broncho-
dilators for 4 and 12 hours respectively, heart rate (HR) and 
peripheral blood pressure were measured (705-IT, Omron, 
Milton Keynes, UK). Mean arterial pressure (MAP) was 
calculated. Aortic pulse wave velocity (PWV) was performed 
after resting supine for 10 minutes using a Sphygmocor 
device (Atcor Medical, West Ryde, Australia) with a single 
experienced operator.10,20 
Anthropometry, lung function, and 
functional tests 
Height and weight (Seca GmbH & Co. KG, Hamburg, 
Germany) were measured and body mass index was 
calculated. Post-bronchodilator spirometry was performed 
using a Microlab MK6 spirometer (Micro Medical Ltd, 
Rochester, UK). The six-minute walking test was performed 
following a standardized protocol using a 10 m course.21 
Handgrip strength was determined from the mean of three 
attempts using the dominant arm. 
Biochemistry
Fasting lipids, liver function tests, and creatine phosphokinase 
were measured on an Olympus AU2700 platform (Beckman 
Coulter, Brea, CA, USA). Low-density lipoprotein cholesterol 
levels were estimated using the Friedewald equation.22 Serum 
was centrifuged, aliquoted, and stored at -80°C for later 
determination of MMP-9 and high sensitivity C-reactive 
protein (hs-CRP). Total MMP-9 was measured in duplicate 
and in batches using an enzyme-linked immunosorbent assay 
kit (R&D Systems, Abingdon, UK). Hs-CRP was measured 
using an immunoturbidimetric assay (Beckman Coulter) on 
an Olympus AU5400 analyzer. 
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Airway inflammatory measurements
Five-flow exhaled nitric oxide (NiOX flex, Aerocrine, Solna, 
Sweden) was used to determine FeNO50, bronchial intercept, 
and alveolar gradient. Induced sputum was performed by 
nebulizing hypertonic saline solution and a differential cell 
count was obtained, both as described in the Supplementary 
material.
Compliance
The tablets remaining at visit two were counted and compared 
with the expected number remaining. Good compliance was 
defined as taking at least 90% of the medication.
sample size
A power calculation based on a 1 m/sec reduction in aortic 
PWV post-treatment, a standard deviation of 1.5 m/sec, a sig-
nificance of 0.05, and a power of 0.8, gave a sample size of 
29 patients per group.23 Given likely attrition, we aimed to 
recruit 35 patients per arm.
Statistical analysis
The data were analyzed using Statistical Package for the Social 
Sciences version 21.0 software (SPSS, Chicago, IL, USA). 
Main analyses compared the difference between the two 
groups in the mean change over 6 weeks. The primary analysis 
was to compare the difference in the mean change in the active 
and placebo arms for aortic PWV using an unpaired t-test. 
A predefined subgroup analysis was performed in patients 
with a baseline aortic PWV measurement 10 m/sec.24–26 
The difference between arms for the change in aortic PWV 
was calculated. A secondary stratified analysis was per-
formed using baseline characteristics thought to influence 
the outcome, including age, sex, and change in MAP, using 
multiple regression analysis. Unless otherwise specified, the 
arithmetic mean and standard deviation was used to show 
central tendency. Positively skewed data, including hs-CRP, 
exhaled nitric oxide measures, and sputum counts were log
10
 
transformed.
Results
Demographics
The sample size was met: of the 70 subjects randomized 
and prescribed treatment, 33 were randomized to the active 
treatment arm (31 completed) and 37 to the placebo arm 
(33 completed), as shown in Figure 1. Baseline demo-
graphics were well matched between groups (see Table 1). 
Baseline lung function and aortic PWV between those who 
dropped out (n=6) and those who completed the study (n=64) 
were similar. 
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Figure 1 CONSORT diagram of study recruitment, allocation, drop-out and completion.
Notes: *Cardiac history, alcohol excess, maintenance prednisolone/antibiotics, withdrew consent, other respiratory diagnosis, never smoker, outside age range. 
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Table 1 Baseline demographics for all subjects
Mean (SD) Unless otherwise specified Active treatment group n=33 Placebo group n=37
Age (years), median (range) 64 (50–79) 65 (50–79)
Male sex, n (%) 26 (79) 24 (65)
Smoking status, (current:ex) n (%) 7 (21):26 (79) 15 (41):22 (59)
Pack years, median (IQR) 41 (30–53) 45 (32–59)
FeV1 (L) 1.6 (0.6) 1.4 (0.5)
FeV1 % predicted 55 (14) 53 (15)
FeV1/FVC 46 (12) 47 (12)
GOLD stage n (II, III) 20, 13 22, 15
Total cholesterol (mmol/L) 5.3 (0.8) 5.4 (0.8)
HDL cholesterol (mmol/L) 1.7 (0.4) 1.7 (0.5)
LDL cholesterol (mmol/L) 3.0 (0.7) 3.0 (0.7)
Abbreviations: FeV1, forced expired volume in one second; FVC, forced vital capacity; GOLD, Global Initiative for Chronic Obstructive Lung Disease; HDL, high-density 
lipoprotein; IQR, interquartile range; L, liter; LDL, low-density lipoprotein; SD, standard deviation.
Aortic PWV and other hemodynamic 
measures 
There was a fall in aortic PWV in the active group of -1 m/sec; 
however, the difference in change between the active and 
placebo arms was not significant (-0.7 [-1.8, 0.5] m/sec, see 
Table 2 and Figure 2). Adjusting for potential confounders 
of age, sex, and change in MAP did not alter this. 
There were no significant changes in central or peripheral 
blood pressure indices between the active treatment and 
placebo arms (see Table 2). 
Multiple linear regression confirmed both MAP and age 
to be independent predictors of baseline aortic PWV. There 
was no relationship between baseline total cholesterol, low-
density lipoprotein cholesterol level, and baseline aortic 
PWV. Aortic PWV was greater in males (9.9 [3.2] m/sec) 
than in females (8.7 [1.8] m/sec, P=0.051).
Hemodynamics in patients with baseline 
aortic PWV 10 m/sec
In the predefined subgroup analysis of subjects with a base-
line aortic PWV 10 m/sec,25,26 n=25 there were n=12 on 
active treatment and n=13 in the placebo group. Of these 
n=22 completed the study – active n=11, placebo n=11. 
The baseline demographics and physiological measures are 
presented in Table S1. There was a significant difference in 
the change in aortic PWV between the active and placebo 
groups of -2.8 m/sec (P=0.03, Table 3 and Figure 2). This 
significant difference remained after adjusting for age, sex, 
and change in MAP (P=0.009). 
Lipids and inflammatory markers
Total and low-density lipoprotein cholesterol levels dropped 
in the active treatment arm compared with the placebo 
arm (both P0.001, Table 2). There were no significant 
 differences in the mean change of total MMP-9 or hs-CRP, 
sputum neutrophil cell counts (n=20), or FeNO measure-
ments (n=36) in the active treatment group compared with 
the placebo group (see Table S2). 
lung function and functional tests
There was no difference in the spirometric and functional tests 
between the active treatment and placebo groups (Table S2). 
Compliance and adverse events
Of the 64 subjects who completed, 15 had poor compliance 
(placebo n=10, active n=5). However, all 64 subjects took 
a minimum of 35 tablets. There were no serious adverse 
events. Patient-reported side effects in both groups were 
musculoskeletal (muscle and joint aches, pain and cramps) 
and respiratory (cough, shortness of breath, and chest infec-
tions) in nature (see Table S3). 
Discussion 
This is the first reported double-blind, randomized, placebo-
controlled trial of statin therapy examining CV endpoints as the 
primary outcome in patients with COPD. Further, it focuses on 
the role of statins as primary prevention in COPD, excluding 
those with known ischemic heart disease, diabetes, or hyperc-
holesterolemia. Overall, there was a nonsignificant reduction 
in the primary endpoint of aortic stiffness following 6 weeks of 
simvastatin 20 mg once daily compared with placebo. In those 
with a high baseline aortic PWV, statin therapy reduced aortic 
PWV when compared with placebo. This trial supports the con-
cept that the increased aortic stiffness in COPD is modifiable 
and that statins may have a primary preventative role in those 
patients with COPD particularly those at greater CV risk. 
Aortic PWV measurements were comparable with those 
in recently published studies of patients with COPD,27,28 but 
lower than initial reports of around 11 m/sec despite these 
International Journal of COPD 2015:10 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
215
statins in COPD
T
ab
le
 2
 C
ar
di
ov
as
cu
la
r 
m
ea
su
re
m
en
ts
 
M
ea
n 
(S
D
) 
n=
to
ta
l  
(a
ct
iv
e 
tr
ea
tm
en
t:
pl
ac
eb
o)
A
ct
iv
e 
tr
ea
tm
en
t 
 
(s
im
va
st
at
in
) 
gr
ou
p
P
la
ce
bo
 g
ro
up
M
ea
n 
di
ffe
re
nc
e 
∆ 
ac
ti
ve
 t
re
at
m
en
t 
ve
rs
us
 ∆
 p
la
ce
bo
 (
C
I)
P-
va
lu
e 
(b
et
w
ee
n 
ar
m
 
ch
an
ge
)
P
re
-
tr
ea
tm
en
t
P
os
t-
tr
ea
tm
en
t
P
os
t-
pr
e 
m
ea
n 
∆
P
re
-
tr
ea
tm
en
t
P
os
t-
tr
ea
tm
en
t
P
os
t-
pr
e 
m
ea
n 
∆
A
or
tic
 P
W
V
 (
m
/s
ec
) 
n=
63
 (
31
:3
2)
9.
9 
(3
.4
)
8.
9 
(2
.2
)
-1
.0
9.
1 
(2
.3
)
8.
9 
(3
.0
)
-0
.3
-0
.7
 (
-1
.8
, 0
.5
)
0.
24
T
ot
al
 c
ho
le
st
er
ol
 le
ve
ls
 (
m
m
ol
/L
) 
n=
64
 (
31
:3
3)
5.
2 
(0
.8
)
4.
1 
(0
.8
)
-1
.2
5.
4 
(0
.8
)
5.
3 
(0
.9
)
-0
.1
-1
.1
 (
-1
.3
, -
0.
8)

0.
00
1
Pe
ri
ph
er
al
 s
ea
te
d 
n=
64
 (
31
:3
3)
Sy
st
ol
ic
 B
P 
(m
m
H
g)
14
7 
(2
2)
14
4 
(1
8)
-3
.1
15
1 
(2
5)
14
5 
(2
4)
-5
.5
2.
4 
(-
3.
7,
 8
.6
)
0.
43
D
ia
st
ol
ic
 B
P 
(m
m
H
g)
90
 (
12
)
87
 (
11
)
-3
.6
88
 (
14
)
86
 (
12
)
-2
.4
-1
.3
 (
-4
.7
, 2
.1
)
0.
45
M
A
P 
(m
m
H
g)
10
9 
(1
4)
10
6 
(1
2)
-3
.5
10
9 
(1
6)
10
5 
(1
5)
-3
.4
-0
.1
 (
-3
.8
, 3
.6
)
0.
98
C
en
tr
al
 s
ea
te
d 
n=
62
 (
30
:3
2)
Sy
st
ol
ic
 B
P 
(m
m
H
g)
13
7 
(1
8)
13
5 
(2
2)
-1
.6
13
8 
(2
3)
13
3 
(2
3)
-4
.9
3.
3 
(-
2.
5,
 9
.0
)
0.
26
D
ia
st
ol
ic
 B
P 
(m
m
H
g)
91
 (
12
)
86
 (
12
)
-4
.1
89
 (
14
)
85
 (
14
)
-2
.2
-1
.9
 (
-5
.5
, 1
.7
)
0.
30
M
A
P 
(m
m
H
g)
11
1 
(1
4)
10
8 
(1
2)
-3
.3
11
0 
(1
8)
10
7 
(1
6)
-3
.3
-0
.1
 (
-4
.1
, 4
.0
)
0.
98
H
R
 (
bp
m
)
73
 (
13
)
73
 (
14
)
-0
.4
74
 (
15
)
76
 (
17
)
2.
3
-2
.7
 (
-6
.1
, 0
.7
)
0.
12
A
bb
re
vi
at
io
ns
: P
W
V
, p
ul
se
 w
av
e 
ve
lo
ci
ty
; B
P,
 b
lo
od
 p
re
ss
ur
e;
 M
A
P,
 m
ea
n 
ar
te
ri
al
 p
re
ss
ur
e;
 H
R
, h
ea
rt
 r
at
e;
 S
D
, s
ta
nd
ar
d 
de
vi
at
io
n;
 C
I, 
co
nfi
de
nc
e 
in
te
rv
al
.
original COPD studies using similar methodology and 
devices.10,11 Age, lung function, and cholesterol levels in 
our patients were similar to other studies in COPD, and our 
exclusion of comorbidities was also comparable.10,27,28 As 
expected, multiple linear regression demonstrated that seated 
MAP and age were predictors of baseline aortic PWV, which 
is reassuring given that age and MAP are major contribu-
tors to aortic PWV,20 but interestingly, aortic PWV was not 
associated with baseline cholesterol. 
The drop of -1 m/sec in aortic PWV with simvastatin 
20 mg over 6 weeks from a baseline of 9.9 m/sec is consis-
tent with a previous study in rheumatoid arthritis,14 and is 
potentially clinically meaningful given that an increase of 
1 m/sec is associated with clinically relevant increases in CV 
events, CV mortality, and all-cause mortality.23 
The large and significant reduction in aortic PWV 
with simvastatin in the subjects with a baseline aortic 
PWV 10 m/sec, a value recently adopted by the European 
Society of Hypertension/European Society of Cardiology as 
indicating increased aortic stiffness,24–26 suggests that such 
therapy may be better directed at those with the greater aortic 
stiffness and CV risk and provides encouragement to con-
sider further investigation in such patients. The magnitude of 
change seen over the 6 weeks is of clinical relevance. 
Low-grade systemic inflammation has been associated 
with a risk of cardiac injury in COPD, and attenuating the 
increased inflammation might reduce CV risk.29 Circulating 
inflammatory markers such as hs-CRP and MMP-9 are ele-
vated in COPD, and patients with COPD and a CRP 3 mg/L 
are at high risk of future CV events.30–32 Just over half of our 
study population was identified as being in this high-risk 
group.
Potential mechanisms of how simvastatin may modulate 
aortic stiffness involve an anti-inflammatory effect and a 
subsequent effect on vascular structure,33 a direct cholesterol-
lowering effect, or improving endothelial function, and 
thereby improving endothelial nitric oxide formation.14,34,35 It 
is likely that these mechanisms are further intertwined with 
each other. In this proof of principle study, 6 weeks of sim-
vastatin treatment did not affect circulating CRP, although 
a previous RCT in patients with COPD reported a reduction 
in CRP levels following 6 months of treatment with pravas-
tatin.36 Circulating MMP-9 levels are associated with aortic 
stiffness in patients with isolated systolic hypertension and 
also in healthy subjects,37 and have previously been modu-
lated by statins, but again, were not affected by statins in our 
study.17 We opted not to study a vast array of inflammatory 
mediators, selecting two that were relevant to COPD and CV 
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Figure 2 Change in aortic PWV for active treatment and placebo groups in (A) the total study group and (B) those with a high baseline aortic PWV. Line represents mean 
drop from baseline. Dotted line indicates active (simvastatin) arm. Black solid line indicates placebo. Error bars indicate the standard error.
Abbreviation: PWV, pulse wave velocity.
Table 3 Patients with a high baseline aortic PWV 10 m/sec 
Mean (SD) n=total  
(active treatment:placebo)
Active treatment  
(simvastatin)
Placebo Mean difference ∆ 
active treatment 
versus ∆ placebo (CI)
P-value (between 
arm change)
Pre-
treatment
Post-
treatment
Pre-
treatment
Post-
treatment
Aortic PWV (m/sec) n=22 (11:11) 13.5 (2.9) 10.6 (2.1) 11.6 (1.5) 11.5 (3.0) -2.8 (-5.2, -0.3) 0.03
Peripheral seated (mmHg) n=22 (11:11)
Systolic BP 158 (27) 152 (20) 162 (31) 159 (26) -3.2 (-15.4, 9.0) 0.59
Diastolic BP 95 (14) 91 (13) 89 (18) 87 (13) -1.6 (-7.7, 4.4) 0.58
MaP 116 (18) 111 (14) 113 (21) 111 (15) -2.2 (-9.5, 5.2) 0.55
Central seated (mmHg) n=20 (10:11)
Systolic BP 147 (23) 142 (20) 145 (30) 142 (27) -1.7 (-11.6, 8.2) 0.73
Diastolic BP 95 (16) 92 (13) 88 (19) 87 (12) -2.0 (-9.1, 5.1) 0.56
MaP 118 (19) 114 (15) 112 (24) 112 (18) -4.4 (-11.4, 2.7) 0.21
Abbreviations: CI, confidence interval; PWV, pulse wave velocity; BP, blood pressure; MAP, mean arterial pressure; SD, standard deviation.
state and had been previously modulated with statins. This 
aside, the effect of statins on vascular wall inflammation, as 
opposed to circulating inflammatory biomarkers, is likely to 
be more relevant mechanistically.17,38
We did not expect nor did we find that simvastatin would 
alter lung function over such a short period. In the general 
population, retrospective observational studies suggest that 
statins may slow the annual rate of decline in lung function.39 
It was encouraging that no decline in the six-minute walking 
distance occurred in the active treatment group compared 
with placebo, as muscular side effects remain a concern 
with statin therapy. 
Although the lack of significant change in hemodynamic 
markers on simvastatin compared with placebo might sug-
gest that statins do not alter these parameters, alternative 
explanations include the short duration of the study, the 
dose, and the aforementioned lower baseline aortic PWV. 
The sample size of 70 as per power calculation was reached; 
however, given the lower baseline results and wider stan-
dard deviation than expected, retrospectively it is likely 
that this study was underpowered. Six weeks was sufficient 
to lower cholesterol, and a longer duration may have been 
confounded by the likelihood of exacerbations that could 
interfere with both CV and inflammatory outcome measures. 
Furthermore, 6 weeks of statin treatment has previously 
been sufficient to detect a change in aortic PWV in studies 
of other chronic inflammatory conditions.14 In clinical prac-
tice, simvastatin would be prescribed as long-term therapy. 
The dose of simvastatin 20 mg once daily was a relatively 
low one, and there is the possibility that a higher dose may 
have shown a better response, but this dose was sufficient 
to significantly lower cholesterol levels and a greater dose 
may have led to a more side effects. We selected a 20 mg 
dose for simvastatin because with a higher dose there is 
a greater risk of musculoskeletal problems and other side 
effects.19 
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Until recently, there have been no pharmacological RCTs 
in COPD with primary CV endpoints, with only observa-
tional or retrospective analyses of RCTs that had primary 
lung endpoints. Since starting this study, a placebo-controlled 
RCT of fluticasone/salmeterol in subjects with COPD, 
including those with stable CV disease, with the primary end-
point of aortic PWV, has been reported.28 Overall, there was 
no beneficial effect on aortic PWV over 12 weeks. However, 
there was a significant improvement in aortic PWV in patients 
with the top tertile (10.9 m/sec) of baseline aortic PWV. 
The primary outcome of the recently published STATCOPE 
study of simvastatin 40 mg once daily was exacerbation, 
with CV events included in the adverse event reporting.18 It 
should be noted that although the results with simvastatin in 
patients with COPD and a higher baseline aortic PWV were 
encouraging, there was some disparity in baseline hemody-
namic measures between the two groups. 
Conclusion
In patients with COPD without ischemic heart disease, 
diabetes, or hypercholesterolemia, simvastatin 20 mg once 
daily for 6 weeks compared with placebo was associated with 
a nonsignificant improvement in aortic stiffness despite a sig-
nificant lowering of cholesterol. In those with high baseline 
aortic PWV, a large and significant reduction in aortic PWV 
was demonstrated on simvastatin compared with placebo. 
This may signify a potential benefit in terms of CV mortality 
in a high-risk group of patients, in whom statins would not 
previously have been routinely considered. 
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Inclusion criteria (protocol available 
on request) 
1) Male or female patients aged 45–80 years 
2) Confirmed chronic obstructive pulmonary disease: 
forced expired volume in one second (FEV
1
) 30%–80% 
predicted, FEV
1 
to forced vital capacity (FVC) ratio 
(FEV
1
/FVC) 0.7, salbutamol reversibility 12% and 
200 mL, supportive smoking history 
3) If female and of childbearing potential, have a negative 
serum pregnancy test at screening and use a medically 
acceptable form of contraception 
4) Able to attend for regular clinic appointments 
5) In opinion of investigator, the patient will be able to 
comply with the requirements of the protocol
6) Provide written informed consent 
exclusion criteria
1) Known hypersensitivity to or side effects relating to pre-
vious statin treatment, or current therapy which includes 
a statin, ezetimibe or fibrate 
2) Clinically significant liver function abnormality; alcohol 
excess (defined as 21 units per week for males or 
14 units for females) 
3) Hypercholesterolemia 6.5 mmol/L
4) Females who are pregnant, breast feeding, or at risk of 
pregnancy and not using a medically acceptable form of 
contraception 
 5)  Any condition judged by investigator that would cause 
the study to be detrimental to patient 
 6) Conditions: 
	 •	 	rheumatoid disease/other collagen vascular disease 
requiring therapy
	 •	 diabetes mellitus 
	 •	 untreated hypothyroidism 
	  •	 inflammatory bowel disease 
	  •	 other respiratory disease
	  •	 malignancy 
	  •	 	documented history of ischemic heart disease; 
cor pulmonale or known congestive heart failure
	  •	 known alpha-1 antitrypsin deficiency 
	  •	 	patients planning to undergo elective surgery during 
the study period. 
 7) Exacerbation in the last 4 weeks
 8) Significant hypoxia (PaO
2
 7.3 kPa)
 9) Known lactose intolerance 
10) Therapies: 
	 	 •	 	oral prednisolone for more than one week in the last 
6 months 
	 	 •	 disease-modifying drugs (eg, gold/sulfasalazine) 
	 	 •	 weight loss drugs
	 	•	 concomitant use of warfarin, cyclosporine 
	 	 •	 	concomitant administration of potent cytochrome 
3A4 inhibitors, eg, itraconazole, ketoconazole, 
human immunodeficiency virus protease inhibitors, 
Supplementary materials
Table S1 Baseline demographics in subjects with a high baseline aortic pulse wave velocity 
Mean (SD) Unless otherwise specified Active treatment (simvastatin) group Placebo
Total number of patients, n 12 13
Age (years), median (range) 70 (54–77) 64 (52–75)
Male sex, n (%) 9 (75) 10 (77)
Smoking status (current:ex) 4:8 5:8
Pack years, median (IQR) 41.5 (33–50) 53 (37–68)
Aortic PWV (m/sec) 13.2 (2.9) 12.0 (2.1)
Peripheral systolic BP (mmHg) 156 (27) 159 (31)
Peripheral diastolic BP (mmHg) 94 (14) 90 (18)
FeV1 (L) 1.4 (0.6) 1.6 (0.7)
FeV1 % predicted 51 (13) 55 (17)
FeV1/FVC 41 (8) 48 (10)
Total cholesterol (mmol/L) 5.3 (0.8) 5.3 (0.8)
HDL cholesterol (mmol/L) 1.7 (0.4) 1.7 (0.5)
LDL cholesterol (mmol/L) 3.0 (0.6) 2.8 (0.7)
Abbreviations: PWV, pulse wave velocity; BP, blood pressure; FEV1, forced expired volume in one second; FVC, forced vital capacity; HDL, high-density lipoprotein; 
IQR, interquartile range; L, liter; LDL, low-density lipoprotein; SD, standard deviation.
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erythromycin, clarithromycin, telithromycin and 
nefazodone. 
	 •	 	use of any investigational drug within 4 weeks of the 
baseline visit.
sputum
Sputum results are not available in all subjects as the induc-
tion procedure could not be performed in everyone. Baseline 
sputum results are only available for 27 subjects (active, 
n=11; placebo, n=16). Of the 43 subjects without results, 
23 could not perform the induction procedure because they 
had a post-bronchodilator FEV
1
 of 50%; nine subjects were 
unable to produce a sputum sample; five produced a sample 
but the slide was uncountable and therefore results could not 
be obtained; and six declined the sputum induction proce-
dure. Sputum was induced by ultrasonic nebulizer (NE-U17, 
Omron, Milton Keynes, UK) using increasing concentrations 
of saline solution -3%, 4%, and 5%.
Sputum plugs were isolated from saliva macroscopically. 
The resulting plugs were mixed with Dulbecco’s phosphate-
buffered saline (1:1) and protease inhibitor (150 µg per gram 
of isolated sputum) by vortexing (FB15012 TopMix, Fisher 
Scientific, Waltham, MA, USA) for 15 seconds before 
pulse sonicating for a further 15 seconds. The suspension 
was then filtered and a quota was removed to assess both 
cell number and viability by mixing with Trypan blue (1:1) 
and analyzing using a hemocytometer. The remaining cell 
suspension was centrifuged (600 g for 10 minutes at 4°C; 
Eppendorf 5702R).
exhaled nitric oxide
Airway inflammation can be assessed using the fraction of 
exhaled nitric oxide (FeNO), which is a repeatable measure in 
subjects with stable chronic obstructive pulmonary disease.1 
Exhaled nitric oxide levels could not be performed in every 
subject at both visits as technical issues were frequently 
encountered. Exhaled nitric oxide was measured using the 
five-flow method (Aerocrine, Solna, Sweden). Two measure-
ments were recorded at each flow rate, and the mean used for 
analysis. Alveolar gradient and bronchial intercept were not 
measured directly, but parameters estimated from a model 
such as the slope-intercept model.2 The alveolar gradient and 
bronchial intercept refer to the regression line through the nitric 
oxide output for each of the flow rates (-10, 30, 50, 100, and 
200 mL/sec). The alveolar gradient corresponds to the alveolar 
concentration and the bronchial intercept corresponds to the 
bronchial nitric oxide flux.3 The machine was calibrated every 
14 days in accordance with manufacturer’s guidance.
International Journal of COPD
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journal
The International Journal of COPD is an international, peer-reviewed 
journal of therapeutics and pharmacology focusing on concise rapid 
reporting of clinical studies and reviews in COPD. Special focus is given 
to the pathophysiological processes underlying the disease, intervention 
programs, patient focused education, and self management protocols. 
This journal is indexed on PubMed Central, MedLine and CAS. The 
manuscript management system is completely online and includes a 
very quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.
International Journal of COPD 2015:10 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
221
statins in COPD
Table S3 Patient-reported side effects and blood tests for safety
Active treatment (simvastatin) group Placebo group
Adverse events/Musculoskeletal
Muscle cramps 2 0
Muscle aches 5 2
Joint aches 0 2
Respiratory 4 3
gastrointestinal 1 1
severe adverse events
hospital admissions 0 0
Death 0 0
Change in lFTs
Clinically relevant increase in ALT 0 0
Clinically relevant increase in gamma GT 1 1
Clinically relevant increased CPK 0 1
Abbreviations: alT, alanine aminotransferase; gamma GT, gamma-glutamyl transferase; CPK, creatine phosphokinase; LFTs, lung function tests.
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